Evidence map›Paper›PMID 37174069›Full record

ArticleCancers2023

Deep Immune Profiling of Multiple Myeloma at Diagnosis and under Lenalidomide Maintenance Therapy.

Sini Luoma, Philipp Sergeev, Komal Kumar Javarappa, Tiina J Öhman, Markku Varjosalo, Marjaana Säily, Pekka Anttila, Marja Sankelo, Anu Partanen, Anne Nihtinen and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Sini LuomaDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-1194-7027
Philipp SergeevInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-0234-1568
Komal Kumar JavarappaInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00290 Helsinki, Finland.
Tiina J ÖhmanInstitute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0001-6647-8873
Markku VarjosaloInstitute of Biotechnology, Helsinki Institute of Life Science, University of Helsinki, 00014 Helsinki, Finland.ORCID 0000-0002-1340-9732
Marjaana SäilyHematology-Oncology Unit, Oulu University Hospital, 90220 Oulu, Finland.
Pekka AnttilaDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0003-0405-0657
Marja SankeloHematology Unit, Department of Internal Medicine, Tampere University Hospital, 33520 Tampere, Finland.
Anu PartanenDepartment of Medicine, Kuopio University Hospital, 70210 Kuopio, Finland.ORCID 0000-0002-5634-2582
Anne NihtinenDepartment of Internal Medicine, North Carelia Central Hospital, 80210 Joensuu, Finland.
Caroline A HeckmanInstitute for Molecular Medicine Finland, Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0002-4324-8706
Raija SilvennoinenDepartment of Hematology, Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, 00290 Helsinki, Finland.ORCID 0000-0001-8939-1586
University of Helsinki · FIKuopio University Hospital · FINorth Karelia Central Hospital · FIOulu University Hospital · FITampere University Hospital · FI

Funding

Cancer Foundation FinlandCelgeneFinnish Cultural FoundationOrion Corporation (Finland) 12NOV2021Signe and Ane Gyllenberg Foundation 5169Sigrid Jusélius Foundation
6 · The paper itself

Abstract

The bone marrow microenvironment interacts with malignant cells and regulates cancer survival and immune evasion in multiple myeloma (MM). We investigated the immune profiles of longitudinal bone marrow samples from patients with newly diagnosed MM (

Indexed as

clinical trialsCyTOFflow cytometryimmunoprofilingmultiple myelomapatient stratification

Identifiers

PMID37174069
PMCPMC10177338
OpenAlexW4376631295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.